Oct 20

Promarker tests now available

Two new blood tests are now available through the Healius Pathology Network, providing GPs with additional information to support clinical decisions in two challenging patient groups.

Proteomics International's Promarker® products are based on the proteins found in individuals with a targeted clinical condition. Proteomics has developed a versatile platform technology for discovering proteins which strongly correlate (positively and/or negatively) with a clinical condition. By comparing blood or other biological samples taken from individuals with and without the condition, our team is able to produce a set of highly specific “biomarkers”. These biomarkers are biological signatures for that condition. When these data are combined with clinical factors in our proprietary clinical algorithm "Promarker Hub", our biomarker-based diagnostics enable clinicians with a window onto individual's unique biochemical activity.

The PromarkerD and PromarkerESO tests are now available via the Healius Pathology Network. Learn more about these tests below. 

See Kidney Risk Earlier

For adults with type 2 diabetes, Promarker®D assesses the risk of developing diabetic kidney disease over the next four years, providing additional insight alongside established kidney assessment.  

Promarker®D is a simple blood test designed to predict the risk of CKD in adults with type 2 diabetes up to four years before symptoms appear.

The test measures blood protein biomarkers linked to kidney disease – Apolipoprotein A4 (ApoA4) and CD5 antigen-like (CD5L) protein – using enzyme-linked immunosorbent assay (ELISA). A clinically validated algorithm combines these results with clinical data (age and eGFR) to calculate the risk score in the proprietary PromarkerD Hub.
Write your awesome label here.

Triage chronic reflux with confidence

PromarkerEso is an in vitro blood test designed to rule out esophageal adenocarcinoma. 

It uses mass spectrometry technology to measure four protein biomarkers 
(alpha-1-antitrypsin, alpha-1-antichymotrypsin, complement C9, and plasma kallikrein) linked with esophageal adenocarcinoma. 

A clinically validated algorithm incorporates these results with clinical risk factor data (BMI, age, sex) to calculate a risk score in the proprietary PromarkerEso Hub cloud-based analysis tool.

Unlike genetic DNA tests that assess acquired risk, PromarkerEso detetcs biologic activity by measuring specific glycoproteins in the blood, which are highly correlated with EAC.
Write your awesome label here.